- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02066350
Cardiovascular Risk Factors After Single Pancreas Transplantation (Diamant)
Assessment of Cardiovascular Risk Factors, Including Endothelial Function, After Restoration of Normoglycemia Following Single Pancreas Transplantation
Patients accepted for the waiting list for single pancreas transplantation suffer from severe glucose instability with hyperglycemia due to diabetes type 1, but do not have significant diabetes-related complications. Pancreas transplantation restores normoglycemia in diabetes type 1 patients with unstable control of glycemia. Both hypo- and hyperglycemic events are abolished, and 70-80 % of the patients obtain satisfactory HbA1c levels (HbA1c 5.0-6.0 %) without the need of exogenous insulin. Endothelial dysfunction is considered as an early and potentially reversible stage in the atherosclerotic process. The endothelium is involved in homeostasis, leucocyte adhesion and vasomotor activity. Reduced endothelium-dependent vasodilation is associated with increments in cardiovascular risk factors, and endothelial dysfunction is a predictor for future cardiovascular disease. It has also been hypothesized that endothelial dysfunction may be involved in the impaired glycemic control by reducing the availability of glucose in peripheral muscles.Establishing normoglycemia by pancreas transplantation alone in previously diabetic type 1 patients has recently been shown to improve left ventricular ejection fraction, assessed by Doppler echocardiographic examination. In diabetic patients receiving a new pancreas it is possible to assess the effect of changing blood glucose excursions on cardiovascular risk factors, including endothelial function, without the use of antidiabetic drugs (exclude pleiotropic effects).
The primary objective of the present study is to assess if endothelial function (assessed by flow-mediated dilatation of arteria brachialis) is improved when hyperglycemia is reversed by single pancreas transplantation in patients with type 1 diabetes.
Secondary objectives are to investigate the changes in the following parameters by reversal of hyperglycemia by pancreas transplantation; Peripheral arterial tonometry, serum/plasma concentrations of endothelial dysfunction markers, blood pressure, lipid and lipoprotein concentrations.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Oslo, Norvège, N-0424
- Oslo University Hospital, Rikshospitalet
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients with type 1 diabetes accepted for the waiting list for single pancreas transplantation
- Healthy volunteers (non-diabetic, non-transplanted)
- Over 18 years of age
- Signed informed consent
Exclusion Criteria:
- Non-functioning pancreas graft (defined as HbA1c ≥ 6.5 % with the need of insulin injections and fasting C-peptide concentration < 300 pmol/L).
- Active infection
- Active autoimmune disease other than diabetes
- Severe liver disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Single pancreas transplantation
This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation.
Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft.
A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Endothelial function
Délai: 1 year post-transplant
|
This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation.
Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft.
Flow-mediated dilatation (FMD) of large vessels (arteria brachialis) will be assessed by measuring vessel diameter by ultrasound and the FMD of micro vessels in the finger tip will be assessed by Endo-PAT (PAT=Peripheral Arterial Tonus) following reactive hyperperfusion induced by occlusion of the artery by a sphygmomanometer cuff.
|
1 year post-transplant
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Peripheral arterial tonometry
Délai: 1 year post-transplant
|
1 year post-transplant
|
|
Changes in cardiac performance
Délai: 1 year post-transplant
|
An echocardiographic examination will be performed to assess changes in cardiac performance, such as left ventricular ejection fraction
|
1 year post-transplant
|
Pulse wave velocity (arterial stiffness)
Délai: 1 year post-transplant
|
Pulse wave velocity, using a SphygmoCor device, measuring arterial stiffness will be performed in addition to pulse wave analysis evaluating the shape and amplitude of the aortic pulse wave.
|
1 year post-transplant
|
Heart rate variability
Délai: 1 year post-transplant
|
Heart rate variability will be assessed, using a Vagus device, analyzing short-term electrocardiogram recordings.
|
1 year post-transplant
|
Plasma concentrations of endothelial dysfunction markers
Délai: 1 year post-transplant
|
Fasting plasma samples (6 mL EDTA vacutainer) will be drawn for determination of relevant markers for endothelial dysfunction, such as von Willebrand factors (vWF) and vascular cell adhesion molecule-1 (VCAM-1).
|
1 year post-transplant
|
Blood pressure
Délai: 1 year post-transplant
|
Blood pressure will be measured seated after ten minutes rest by Dyna Map (Tuff.-Cuff,
CAS Medical system Inc.) and the mean of the lower two out of three measurements will be used.
|
1 year post-transplant
|
Lipid and lipoprotein concentrations
Délai: 1 year post-transplant
|
1 year post-transplant
|
|
Bone mineral density and body composition
Délai: 1 year post-transplant
|
Measurement of bone mineral density, using low dosage radiation (dual-energy X-ray absorptiometry (DEXA) scan) to assess the amount (grams) of mineral that are packed into a segment of bone.
In addition a body composition (visceral fat, metabolic measurement) will be determined using the DEXA scan.
|
1 year post-transplant
|
Glomerular filtration rate
Délai: 1 year post-transplant
|
Renal function, defined as glomerular filtration rate, will be evaluated by measuring iohexol clearance.
The concentration of iohexol (Omnipaque), a low dose non-ionic x-ray contrast medium of low osmolality, extensively used in clinical radiology and considered essentially free from side effects, will be measured 2 hours and 5 hours after iv injection of iohexol.
Like other iodine-containing contrast media, it is completely eliminated from the body by excretion in the urine, thus it is an ideal marker for kidney function.
It will be quantitated by chemical measurement based on the determination of iodine.
|
1 year post-transplant
|
Oral glucose tolerance test
Délai: 1 year post-transplant
|
Measurements of plasma glucose, C-peptide and serum insulin before, 30 and 120 minutes following an oral administration of 75 g glucose.
|
1 year post-transplant
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Trond G Jenssen, Professor, Oslo University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2013/1062
- 2013047 (Autre subvention/numéro de financement: South-Eastern Norway Regional Health Authority)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète de type 1
-
Eledon PharmaceuticalsRetiréDiabète sucré de type 1 fragileÉtats-Unis
-
Ain Shams UniversityInconnueDiabète sucré de type 1 avec hypoglycémie | diabète de type 1Egypte
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)ComplétéDiabète sucré de type 1 | DT1 | DT1 | Diabète sucré de type 1 d'apparition récenteÉtats-Unis, Australie
-
Medical College of WisconsinRecrutementDiabète de type 1 | Diabète sucré de type 1 | diabète de type 1États-Unis
-
Spiden AGDCB Research AGComplétéDiabète sucré de type 1 | Diabète sucré de type 1 avec hypoglycémie | Diabète sucré de type 1 avec hyperglycémieSuisse
-
Capillary Biomedical, Inc.ComplétéDiabète sucré, type 1 | Diabète de type 1 | Diabète sucré de type 1 | Diabète sucré, dépendant de l'insuline, 1Australie
-
Shanghai Changzheng HospitalRecrutementDiabète sucré de type 1 fragileChine
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of...InconnueDiabète sucré de type 1 avec hyperglycémie | Diabète sucré de type 1 avec hypoglycémiePologne
-
Poznan University of Medical SciencesInconnueDiabète sucré de type 1 | Rémission du diabète de type 1 | Complications chroniques du diabètePologne
-
University of California, San FranciscoJuvenile Diabetes Research FoundationComplétéDiabète sucré de type 1 | Diabète sucré, type I | Diabète sucré insulino-dépendant 1 | Diabète sucré, dépendant de l'insuline, 1 | IDDMÉtats-Unis, Australie
Essais cliniques sur Single pancreas transplantation
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Pas encore de recrutementLa dépression | Qualité de vie | Phase terminale de la maladie rénale | Handicap PhysiqueÉtats-Unis
-
Massachusetts General HospitalDana-Farber Cancer InstituteComplétéLymphome de Hodgkin | La leucémie lymphocytaire chronique | Lymphome de bas grade | Lymphome diffus à grandes cellules B | Lymphome T | Lymphome à cellules du manteau | Lymphome à petits lymphocytesÉtats-Unis